You have changed your country from  to  . Please be aware that this will change the currency in the purchasing process.

Related products

Reassurance, Refunds & Replacements

If your product does not perform as described on this datasheet, we will refund or replace your product...

Read our guarantee »
 

Anti-Nicotinic Acetylcholine Receptor alpha 1 antibody (ab65832)

CodeSizePriceAbpointsAvailability
    
 
  • -
  •   
  •   
  •   
  •  
  •   
  •   
Updating...

Overview

Product name

Anti-Nicotinic Acetylcholine Receptor alpha 1 antibody
See all Nicotinic Acetylcholine Receptor alpha 1 products (3) ...

Description

Rabbit polyclonal to Nicotinic Acetylcholine Receptor alpha 1

Tested applications

WB, IHC-Pmore details

Cross reactivity

Reacts with

Mouse, Rat, Human

Immunogen

Synthetic peptide (Human) corresponding to a sequence at the N terminus of Nicotinic Acetylcholine Receptor alpha 1, identical to the related mouse and rat sequence.

Positive control

IHC-P: Rat brain tissue WB: Rat brain lysate

Properties

Form

Liquid

Storage instructions

Shipped at 4°C. Upon delivery aliquot and store at -20°C. Avoid freeze / thaw cycles.

Storage buffer

Preservative: 0.02% Sodium Azide, 0.01% Thimerosal (merthiolate)
Constituents: 2.5% BSA, 0.45% Sodium chloride, 0.1% Dibasic monohydrogen sodium phosphate

Concentration

Concentration information loading...

Purity

Immunogen affinity purified

Clonality

Polyclonal

Isotype

IgG

  • Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Nicotinic Acetylcholine Receptor alpha 1 antibody (ab65832)Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Nicotinic Acetylcholine Receptor alpha 1 antibody (ab65832) image (enlarge)

  • Western blot - Nicotinic Acetylcholine Receptor alpha 1 antibody (ab65832)Western blot - Nicotinic Acetylcholine Receptor alpha 1 antibody (ab65832) image (enlarge)

Applications

Show applications key

Our Abpromise guarantee covers the use of ab65832 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

  • ShowHide1 Image

    WB

     WB: Use a concentration ...Read more →

    WB: Use a concentration of 1 - 2 µg/ml.Detects a band of approximately 54 kDa (predicted molecular weight: 54 kDa).

  • ShowHide1 Image

    IHC-P

     IHC-P: Use a concentrati...Read more →

    IHC-P: Use a concentration of 1 - 2 µg/ml.

Target

Function

After binding acetylcholine, the AChR responds by an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane.

Tissue specificity

Isoform 1 is only expressed in skeletal muscle. Isoform 2 is constitutively expressed in skeletal muscle, brain, heart, kidney, liver, lung and thymus.

Involvement in disease

Defects in CHRNA1 are a cause of multiple pterygium syndrome lethal type (MUPSL) [MIM:253290]. Multiple pterygia are found infrequently in children with arthrogryposis and in fetuses with fetal akinesia syndrome. In lethal multiple pterygium syndrome there is intrauterine growth retardation, multiple pterygia, and flexion contractures causing severe arthrogryposis and fetal akinesia. Subcutaneous edema can be severe, causing fetal hydrops with cystic hygroma and lung hypoplasia. Oligohydramnios and facial anomalies are frequent.
Note=The alpha subunit is the main focus for antibody binding in myasthenia gravis. Myasthenia gravis is characterized by sporadic muscular fatigability and weakness, occurring chiefly in muscles innervated by cranial nerves, and characteristically improved by cholinesterase-inhibiting drugs.
Defects in CHRNA1 are a cause of congenital myasthenic syndrome slow-channel type (SCCMS) [MIM:601462]. SCCMS is the most common congenital myasthenic syndrome. Congenital myasthenic syndromes are characterized by muscle weakness affecting the axial and limb muscles (with hypotonia in early-onset forms), the ocular muscles (leading to ptosis and ophthalmoplegia), and the facial and bulbar musculature (affecting sucking and swallowing, and leading to dysphonia). The symptoms fluctuate and worsen with physical effort. SCCMS is caused by kinetic abnormalities of the AChR, resulting in prolonged endplate currents and prolonged AChR channel opening episodes.
Defects in CHRNA1 are a cause of congenital myasthenic syndrome fast-channel type (FCCMS) [MIM:608930]. FCCMS is a congenital myasthenic syndrome characterized by kinetic abnormalities of the AChR. In most cases, FCCMS is due to mutations that decrease activity of the AChR by slowing the rate of opening of the receptor channel, speeding the rate of closure of the channel, or decreasing the number of openings of the channel during ACh occupancy. The result is failure to achieve threshold depolarization of the endplate and consequent failure to fire an action potential.

Sequence similarities

Belongs to the ligand-gated ion channel (TC 1.A.9) family. Acetylcholine receptor (TC 1.A.9.1) subfamily. Alpha-1/CHRNA1 sub-subfamily.

Cellular localization

Cell junction > synapse > postsynaptic cell membrane. Cell membrane.

Target information above from: UniProt accessionP02708 The UniProt Consortium
The Universal Protein Resource (UniProt) in 2010
Nucleic Acids Res. 38:D142-D148 (2010).

Information by UniProt

Alternative names

  • Acetylcholine receptor protein alpha chain Precursor antibody
  • Acetylcholine receptor subunit alpha antibody
  • ACHA_HUMAN antibody
  • ACHRA antibody
  • CHNRA antibody
  • Cholinergic receptor nicotinic alpha polypeptide 1 antibody
  • Cholinergic receptor, nicotinic, alpha polypeptide 1 (muscle) antibody
  • CHRNA1 antibody
  • Nicotinic cholinergic receptor alpha 1 antibody
  • Schizophrenia neurophysiologic defect candidate antibody
see all

Anti-Nicotinic Acetylcholine Receptor alpha 1 antibody images:

  Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Nicotinic Acetylcholine Receptor alpha 1 antibody (ab65832)

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Nicotinic Acetylcholine Receptor alpha 1 antibody (ab65832)

ab65832, at 2µg/ml, staining Nicotinic Acetylcholine Receptor alpha 1 in paraffin embedded rat brain tissue sections by Immunohistochemistry.

  Western blot - Nicotinic Acetylcholine Receptor alpha 1 antibody (ab65832)

Western blot - Nicotinic Acetylcholine Receptor alpha 1 antibody (ab65832)

Anti-Nicotinic Acetylcholine Receptor alpha 1 antibody (ab65832) at 2 µg/ml + rat brain lysate

Predicted band size : 54 kDa
Observed band size : 54 kDa
Additional bands at : 39 kDa. We are unsure as to the identity of these extra bands.

References for Anti-Nicotinic Acetylcholine Receptor alpha 1 antibody (ab65832)

ab65832 has not yet been referenced specifically in any publications.

Publishing research using ab65832? Please let us know so that we can cite the reference in this datasheet

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"